With potential FDA approval on the horizon, Enhertu could be a useful option for many breast cancer patients in 2025
This data is compelling, but remember, plenty of weight loss medications are available now that people do well on, whether thats semaglutide by itself, tirzepatide, or other options (more on that below)
Two of the three groups were transitioned from WD to LD for 5 days before the start of the study
H.MadisonD
NSL literature pointer PMID 33894838 Cagrilintide laboratory index [PMID: 33894838] National Science Labs indexing note for PMID 33894838: review the PubMed methods, models, and limitations before citing
[12] Nevertheless, individuals with conditions affecting copper metabolism such as Wilson's disease should seek specialist medical advice before use